• Seeking Alpha

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Seeking Alpha / 3 hours ago 1 Views

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –

Read more
  • Source:
  • GlobeNewswire - News about Public Companies
Previous post
Waters Corporation Schedules Second Quarter 2025 Earnings Conference Call
Next post
VERTEX Strengthens Leadership Team with Key Executive Appointments and New Board Members

Comments

Just Posted

  • Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

    3 hours ago

  • ZenaTech reacciona al memorando "Impulsando el dominio de drones militares en EE. UU.": una directiva de política revolucionaria para ZenaDrone

    10 hours ago

  • Seniors Helping Seniors® In-Home Care Services Expands in Southwest Atlanta, Georgia

    16 hours ago

  • Sezzle, Futu, SoFi, MGIC among week's biggest financial movers

    20 hours ago

  • Notable analyst calls this week: Tesla, Microsoft and Illumina among top picks

    20 hours ago

Tags

  • SA Transcripts
  • TOU:CA
  • Gold Mining Bull
  • TPZ
  • NG1:COM
  • CHK
  • TRMLF
  • fivn
  • CGIFF
  • CHE.UN:CA

Reviews

Categories

  • Seeking Alpha 95

Categories

  • Seeking Alpha 95

Pages

Tags

  • SA Transcripts
  • TOU:CA
  • Gold Mining Bull
  • TPZ
  • NG1:COM
  • CHK
  • TRMLF
  • fivn
  • CGIFF
  • CHE.UN:CA

Copyright News That Move � 2018. All Rights Reserved

  • Seeking Alpha
  • Trade Halts